Intuitive Surgical (ISRG)
(Delayed Data from NSDQ)
$486.62 USD
+1.86 (0.38%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $487.17 +0.55 (0.11%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$486.62 USD
+1.86 (0.38%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $487.17 +0.55 (0.11%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Zacks News
Market Share Gains Aid Zimmer Biomet Stock Amid Cost Pressure
by Zacks Equity Research
In terms of Persona cementless Knee, ZBH is currently witnessing strong uptake of the cementless platform Persona OsseoTi.
New Launches Support Tandem Diabetes Stock Despite Macro Concerns
by Zacks Equity Research
The latest addition to TNDM's pump platform portfolio, Tandem Mobi, is leading the way in creating a whole new category of devices for insulin therapy.
Intuitive Surgical, Inc. (ISRG) Stock Moves 1.03%: What You Should Know
by Zacks Equity Research
The latest trading day saw Intuitive Surgical, Inc. (ISRG) settling at $487.17, representing a +1.03% change from its previous close.
Phibro Q4 Earnings and Revenues Beat, Operating Margin Down
by Zacks Equity Research
PAHC's impressive fourth-quarter fiscal 2024 results can be attributed to the Animal Health segment's robust performance.
Neogen Suffers From Competitive Pressure, Macroeconomic Woes
by Zacks Equity Research
NEOG faces intense competition, which could affect the marketability and profitability of its products.
ABT Expands Pure Bliss Line of Products for Advanced Infant Nutrition
by Zacks Equity Research
Abbott announces the expansion of its Pure Bliss by Similac line of products for infant nutrition with Organic and Organic A2 Milk infant formulas.
Investors Heavily Search Intuitive Surgical, Inc. (ISRG): Here is What You Need to Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Intuitive Surgical (ISRG). This makes it worthwhile to examine what the stock has in store.
Quest Diagnostics Expands in North America With New Acquisition
by Zacks Equity Research
DGX acquires 100% of LifeLabs from OMERS, at approximately $1 billion. It will help LifeLabs to improve healthcare for Canadians.
Reasons to Retain QIAGEN Stock in Your Portfolio Now
by Zacks Equity Research
Investors remain optimistic about QGEN due to its progress in test menu expansion and impressive prospects within its molecular diagnostics segments.
Ekso Bionics (EKSO) Addressable Market to Grow on CMS Update
by Zacks Equity Research
The CMS reimbursement is pivotal for Ekso Bionics (EKSO), as it opens up substantial opportunities in a market where cost has often been a barrier to access
Reasons to Retain ICON (ICLR) Stock in Your Portfolio Now
by Zacks Equity Research
Investors remain optimistic about ICON (ICLR) due to its commitment to patient access and impressive strategic pacts.
SI-BONE (SIBN) Receives FDA Nod for Its TNT Implant System
by Zacks Equity Research
SI-BONE (SIBN) receives FDA 510(k) clearance for its iFuse TORQ TNT implant system, followed by a Breakthrough Device Designation award by the FDA.
Intuitive Surgical, Inc. (ISRG) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
Intuitive Surgical, Inc. (ISRG) concluded the recent trading session at $486.55, signifying a -0.79% move from its prior day's close.
Microbot Medical (MBOT) Inks New Phase 2 Agreement for LIBERTY
by Zacks Equity Research
Microbot Medical (MBOT) signs a Phase 2 collaboration agreement with Corewell Health to advance remote telesurgery for endovascular procedures using LIBERTY.
Henry Schein (HSIC) Hurt by Macroeconomic Woes, Cyber Attacks
by Zacks Equity Research
With sustained macroeconomic pressure, Henry Schein (HSIC) struggles to keep in check its cost of revenues and operating expenses.
Edwards Lifesciences (EW) Up 19.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Reasons to Retain Bio-Rad (BIO) Stock in Your Portfolio Now
by Zacks Equity Research
Bio-Rad's (BIO) robust digital PCR business and Clinical Diagnostics segments raise optimism. However, macro issues raise concerns.
Globus Medical's (GMED) Lateral Interbody Portfolio Gets New Launch
by Zacks Equity Research
Globus Medical's (GMED) lateral interbody portfolio gets its first commercial product launch with ADIRA XLIF Plate System.
IQVIA (IQV) Up 3.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
IQVIA (IQV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Reasons to Retain Thermo Fisher (TMO) in Your Portfolio Now
by Zacks Equity Research
Strategic alliances and impressive product launches bode well for Thermo Fisher (TMO).
Omnicell (OMCL) Introduces Central Med Automation Service
by Zacks Equity Research
Omnicell (OMCL) has come up with a subscription-based solution named Central Med Automation Service. The solution is expected to improve inventory visibility, scalability and patient safety.
This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.
Alcon (ALC) Q2 Earnings Meet Estimates, Revenues Increase Y/Y
by Zacks Equity Research
Alcon (ALC) delivers impressive growth in Implantables and Contact Lenses in the second quarter of 2024.
Medtronic (MDT) Q1 Earnings Beat, Fiscal 2025 View Narrowed
by Zacks Equity Research
Medtronic (MDT) reports broad-based growth across all major segments, with strong gains in Cardiac Rhythm & Heart Failure, Structural Heart & Aortic, Cranial & Spinal Technologies and Diabetes businesses.
NeuroPace (NPCE) Q2 Earnings Beat, '24 Sales View Up
by Zacks Equity Research
NeuroPace's (NPCE) top and bottom lines outpace estimates in the second quarter.